Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 16th Global Summit on Hematology and Infectious Diseases London, UK.

Submit your Abstract
or e-mail to

hematologycongress@globalannualmeet.com
blooddisorders@meetingsnexpo.com
hematologycongress@globalannualmeet.com

Scientific Program Day 1

Day 1 :

Keynote Forum

Ilham Youssry

Cairo University, Egypt

Keynote: Professor

Time : 10:20-10:45

Conference Series World Infectious Diseases 2020 International Conference Keynote Speaker Ilham Youssry photo
Biography:

Prof. Ilham Youssry, MD professor of Pediatrics, Cairo University and Head of the Pediatric Hematology and Bone Marrow Transplantation (BMT) Unit, Cairo University. Dr. Ilham received training in Pediatrics and Pediatric Hematology in New Children Hospital, Cairo University &Tokyo National Cancer Centre (NCC), Japan & Southern Illinois University, USA & The Royal London Hospital and in the BMT unit at St Mary’s Hospital Paddington, UK. Professor. Ilham is an international Certified Trainer from the International Board of Certified Trainers (IBCT), Netherland. Professor Ilham received a master’s degree in Health Profession Education from Maastricht University and Suez Canal University. In 2012 she completed training in a 2-year program in Foundation of Advanced International Medical Education and Research (FAIMER), Philadelphia, USA. Professor Ilham was the director of the Pediatric Hematology and Bone Marrow Transplantation

(BMT) Unit, Cairo University from 2011 to 2015, during this time she initiated BMT service for a growing number of thalassemia and
aplastic anemia patients. She is the supervisor of more than 50 MD & MSc theses on Thalassemia, Sickle Cell anemia, Spherocytosis,
Gaucher disease, Aplastic Anemia, Thrombocytopenia and Hemophilia. She has more than 40 publications in national and international journals. Dr. Ilham was a speaker and chairperson in many national and international scientific meetingsjournals. Dr. Ilham was a speaker and chairperson in many national and international scientific meetings.

Abstract:

Background and Purpose: The pathophysiology of sickle cell disease (SCD) is complex and heterogeneous. Since described by Dr. James B. Herrick in 1910, there have been improvements in the understanding of the cellular dysfunctions that occur due to hemoglobin polymerization and that lead to multi-organ damage in
this disease. Novel therapies are a result of such understanding of the pathophysiology of SCD. Methods: we conducted a PubMed search for articles published up to June 15, 2019, using the search terms “sickle cell disease,” “curative therapies,” “anti-oxidant,” “anti-adhesive agent,” “anti-inflammatory,” “anticoagulant,” “novel anti-sickling agents and HbF inducers,” “delay production of oxyHb.” Studies cited include case series, retrospective studies, prospective clinical trials, meta-analyses, online abstracts, and original reviews.
Results: The only approved long-life supportive therapy for SCD is the use of prophylactic penicillin, hydroxyurea, blood transfusion to decrease strokes and L-glutamine. However, HLA matched bone marrow transplantation is the only approved curative therapy for selected patients. The approved therapies for SCD over the last decades have improved life expectancies but have not solved many of the disease’s morbidities. Thus, many clinical trials are currently being conducted for testing novel multimodality agents that target different contributing pathophysiologic processes such as: agents that target the DNA mutation defects (curative therapies), hemoglobin polymerization (anti-sickling agents) and many other targeted therapies that counter-act cellular adhesion, inflammation, oxidant injury and platelets and/or coagulation. Conclusion: Deeper insights into the pathophysiology of SCD have led to the development of novel agents that target different contributing pathophysiologic processes.

Keynote Forum

Victor Lage de Araujo

CAP Evidence-Based Healthcare, UK

Keynote: Doctor

Time : 10:45-11:20

Conference Series World Infectious Diseases 2020 International Conference Keynote Speaker Victor Lage de Araujo photo
Biography:

 
Victor Lage de Araujo has completed his MSc Evidence-Based Healthcare at the University College London, at 2019. He is a Brazilian physician – Board specialities: Clinical Chemistry, Hemotherapy and Healthcare-Associated Infection Control – and practices Clinical Pathology at Brazil. Victor is a member of the Brazilian Society for Clinical Pathology/Laboratory Medicine and International Fellow of the College of American Pathologists (CAP). For his Title as Laboratory Physician, he has presented a study on combined measures in Blood Management in orthopaedic surgical patients. He is a Polyglot (Portuguese-BR, English, Spanish, French, German and Dutch) and Medical Translator.

Abstract:

Hemotherapy has been deservedly considered a heroic therapy, despite some adverse effects. After the HIV pandemics, awareness about transfusion-associated diseases (e.g. HIV, HBV/HDV, HCV and HTLV virus; the protozoan Trypanosomiasis and Malaria) challenged us to associate chronic diseases to trans fusional events. Notwithstanding excellent diagnostic tools, a significative probability of transmission remains. Acute Transfusion Reactions are rare; those findings have increased consciousness about subtle immunohematology troubles. Despite ABO/Rh compatibility, about 20 different remaining antigen systems are the root of Erythroblastosis fetalis and delayed haemolysis. Modern hemotherapy uses fractioned Hemecomponents rather than whole blood – Meaning optimisation of the blood supply and focused therapeutics.
However, further technologies are paramount for Patient Blood Management. Determining the patient’s iron profile will assure his haematopoiesis is at its best before surgery. The management of selected patients with supplements and recombinant human erythropoietin shows favourable results. A previous autologous blood donation will result in the availability of those units post-operatively. It is possible to program a preoperatory haemodilution (i.e. calculated harvesting of blood in the immediate preoperatory). The surgical losses will be of lesser concentration, and the blood will be available post-operatively. Through the process of “cellsaving”, blood picked from the surgical site is aseptically processed into concentrated Red Blood Cells (in isotonic saline) for an immediate return. The personalisation of laboratory Ht/Hb decision thresholds limits transfusion with the substitution for alternatives. For patients requiring chronic regimens, judicious use means saving excessive use and increasing tolerance.

Keynote Forum

Thomas Moehler

Global Head of Medical and Scientific services Hematology/Oncology, IQVIA, Germany

Keynote: Dr.
Conference Series World Infectious Diseases 2020 International Conference Keynote Speaker Thomas Moehler photo
Biography:

Thomas Moehler is a Global Head at Medical and Scientific services Hematology/ Oncology (Drug development), IQVIA Germany. He has
a 8 yrs. of Experience in respective field. He has completed his Post-Doctoral Fellowship from The Scripps Research Institute Department
of Vascular Biology and Immunology in 1996-1998, Doctoral Thesis from German Cancer Research Center.

Abstract:

Keynote Forum

Shivanthi Samarasinghe

De Montfort University, UK

Keynote: Professor

Time : 11:20-11:55

Conference Series World Infectious Diseases 2020 International Conference Keynote Speaker Shivanthi Samarasinghe photo
Biography:

Dr S. Samarasinghe’s research career commenced with securing a highly internationally competitive Darwin Trust of Edinburgh doctoral scholarship to work under a world-leading Molecular Microbiologist, Professor Steve Busby, FRS (University of Birmingham) to study the molecular mechanisms that control the gene expression in Escherichia coli. After completing her doctoral studies, she complted a Post-doctoral Research position (2008-2011) at the University of Leicester to understand the molecular mechanisms that control the cell division of higher Eukaryotic Microbes. During that time she was selected as a Visiting Research Fellow at a most prestigious Molecular biology research Lab, European Molecular Biology Laboratory, (EMBL), Germany. Presently, the focus of her scientific research is to understand the underlying genetic characteristics of antibiotic-resistant bacteria associated with Urinary Tract Infections (UTIs), and how these characteristics can be manipulated to combat resistance via developing novel anti-microbial therapies.

Abstract:

In light of the limited therapeutic options and significant threat associated with infections caused by Carbapenem Resistant Enterobacteriaceae (CRE) pathogens, understanding the pathogens’ biology, specifically, the ability of form the biofilms and biofilm related gene expression are utmost important to the treatment of the biofilm-associated infections caused by these CRE pathogens. To understand the pathogenic role of the biofilms, the study investigated amount of biofilm formation and biofilm-related gene expression in in CRE strains, Escherichia coli IMP-type and Klebsiella pneumoniae NDM- 1. The amount of biofilm formed was measured using Tissue Culture plate assay at different time points (6, 12, 24 and 48 hours) of incubation, assuming the time points were corelate with the stages of biofilm development stages; initial attachment (6 hours), microcolony formation (12 hours), maturation of biofilms (24 hours) and dispersion of biofilm (48 hours). Biofilms were quantified under static and shaking incubator conditions and under two different growth media; nutrient poor (AB broth) and nutrient rich media (LB broth) media. In parallel, Quantitative Real-time PCR (qPCR) was applied for invitro biofilm development stages. The amount of biofilms formed and the biofilm-related gene expression results were compared with structural analysis using Confocal Laser Scanning Microscopy (CLSM) at different growth conditions. For both CRE strains irrespective of incubation condition and growth media, varying amount of biofilm was observed and was corelated with the biofilm development stages. Maximum amount of biofilm development was observed at 24 hour time period of incubation indicating the maturation of biofilm development. Similarly, the same pattern of biofilm-related gene expression was observed, where majority of gene expressed at 24 hour time point. In related to the above analysis CLSM also, showed that aggregation of the different cellular products, corresponding to each biofilm development stage. These findings suggested that, for both CRE organisms’ biofilm formation and biofilm-related gene expression profiles are not affected by the various growth conditions tested, indicating the successful pathogenic role of biofilm formation by adopting to different environmental conditions. The findings suggest that adoptability of biofilm under different environmental conditions plays a significant role in the carbapenem-resistant Escherichia coli IMP-type and Klebsiella pneumoniae NDM-1 bacteria in their increased prevalence in biofilm-associated infections.

Keynote Forum

Maha El Taweel

Cairo University, Egypt

Keynote: Professor
Conference Series World Infectious Diseases 2020 International Conference Keynote Speaker Maha El Taweel photo
Biography:

Dr Maha El Taweel has completed her MD PhD from National Cancer Institute, Cairo University, Egypt, 2002. She finished her diploma from France in Cytogenetics (DIU), 2008 and research studies (CRA) in Mcmaster University, Canada, 2017. She has published many papers in different international journals in the field of Hematological malignancies.

Abstract:

Protein Phosphatase 2A (PP2A) is a crucial regulator of the cellular signalling pathways, proliferation, cell cycle checkpoints and apoptosis. The PPP2R5C gene encodes PP2A regulatory B56c subunit. Malignant transformation may occur, if mRNA of PPP2R5C is functionally deregulated, structurally altered, decreased or overexpressed. Therefore, the purpose of the study was to examine PPP2R5C mRNA expression, evaluate
its association with the different clinical and haematological parameters and determine its prognostic impact in Egyptian adult acute myeloid leukaemia patients with normal cytogenetics (CN-AML). Peripheral blood samples of 50 de novo CN-AML patients and 20 age- and gender-matched healthy controls were examined for PPP2R5C expression by Quantitative Real Time-Polymerase Chain Reaction. The expression levels of PPP2R5C mRNA were significantly higher in the CN-AML samples than in the control samples (P ≤ 0.001). There was a statistically significant difference between the low and high expression levels of PPP2R5C with regard to age (P = 0.005, r = - 0.447, P = 0.001). The patients with an unfavourable response to induction chemotherapy had significant higher PPP2R5C expression levels than those with a favourable response (P
= 0.002). There was a significant influence of high PPP2R5C expression levels on the overall survival and progression free survival (P = 0.03, 0.026), respectively. PPP2R5C overexpression is an adverse prognostic factor which affects leukaemogenesis in the CN-AML, it may predict the disease progression and overall survival during the follow-up of the patients.

Keynote Forum

Oscar Marin

Keynote: Professor
Biography:

Oscar Marin has completed his medical degree at the age of 26 years from La Plata-University, Argentina University, Medical Doctor from BuenoAires University-Argentina and postdoctoral studies from Medical Academy of Medicina, Buenos Aires, Argentine, Tokyo Medical and Dental University, and the Cancer Institute, Tokyo by JICA (Japan International Cooperative Agency) and He is the head of Pathology Service in Pablo Soria Hospital, Jujuy-Argentina. He has published papers in reputed international and argentinean journals, and has been serving as an editorial board in the Electronic Journal of Biomedicine, also was speaker in several medical meetings in Argentina, Brasil, Japan and Kiev-Ukraine and presente many works in argentinean and international pathology congresses including the USCAP (United State and Canadian Academy of Pathology.

Abstract:

Jujuy-NW-Argentina, a state near the Andes Mountains presents a high incidence of hematolymphoid malignancies. According to RITA -acronym for Institutional Hospital registry of Tumors of Argentinabelonging to the National Cancer Institute, considering by organ and systems, Hematolymphoid malignancies are overcome only by female genital system tumors, showing a high number of cervix uterine cancer. Non- Hodgkin lymphoma shows the higher incidence, and high grade B-cells lymphomas show relationship with viral agents as Human Immunodeficiency Virus (HIV), Epstein-Barr Virus (EBV), Human Herpes Virus Type-8 (HHV-8) especially in a number of Diffuse Large B-cell Lymphomas (DLBCL) and clinicopathological variants. In low grade lymphomas bacterial association is found, in gastric MALT-Lymphoma wit Helicobacter pylori and in the Immunoproliferative Small Intestine Disease (IPSID) lymphoma with Campylobacter jejuni. Also a case of Marginal zone lymphoma of the MALT-type occurring in the setting of Post-Transplant organ recipient shows signal for EBV, by LMP-1 (Latent Membrane Protein) and EBER-1. Among T-cell lineage lymphomas a relationship with Human T-cell Lymphotropic Virus type 1 (HTLV-1) is found by using serologic test for HTLV-1 in native aboriginal people. In the third lymphoid lineage, the NK/T-cell lymphomas show a strong relationship with EBV established by EBER-1 -the Epstein–Barr virus-encoded small RNAs (EBERs)-. Also Hodgkin lymphomas show a relationship with EBV. Among our cases of T-cell lymphomas the relationship with HTLV-1 is found by using serologic tests for antibodies to HTLV-1 by means ELISA (Enzyme-Linked ImmunoSorbent Assay) Southern Blot and CMIA (quimioluminiscency). EBV was testes by using EBER-1 and LMP-1.Macromolecular immunoactive polysaccharides, glucans, are now available for the prophylaxis of viral, bacterial or fungal infection. They can gently induct or modify of immunity without hyperstimulation. A successful example of using glucans for anti-viral treatment is the pharmaceutical called Kagocel. It is based on highly standardized chemically modified both natural polyphenol and immunoactive cellulose betaglucan. The commercial success of this drug in the Russian pharmaceutical market is due to its excellent safety and efficacy record over fifteen years. The antiviral efficacy of Kagocel against influenza infection has been confirmed in vitro and in vivo in relation of different strains H3N2 and H1N1 influenza viruses, including H1N1pdm09